BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Association of Pulmonary Advanced Practice Providers (APAPP) - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Association of Pulmonary Advanced Practice Providers (APAPP)
X-ORIGINAL-URL:https://www.pulmapp.com
X-WR-CALDESC:Events for Association of Pulmonary Advanced Practice Providers (APAPP)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Denver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20250309T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20251102T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20260308T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20261101T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20270314T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20271107T080000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20250309T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20251102T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20260308T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20261101T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20270314T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20271107T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260922T180000
DTEND;TZID=America/New_York:20260922T190000
DTSTAMP:20260922T124300
CREATED:20260918T160328Z
LAST-MODIFIED:20260918T160328Z
UID:19663-1790100000-1790103600@www.pulmapp.com
SUMMARY:Optimizing ILD Management with Dr. Rohit Gupta
DESCRIPTION:Through discussions of real-world cases\, learners will explore standardized multidisciplinary referral pathways\, shared decision-making strategies\, and approaches to support consistent follow-up and optimize patient-centered outcomes in fibrosing ILDs. Point-of-care tools\, such as a personalized poster portal\, diagnosis wizard\, patient journey tool\, and microlearning resources\, will reinforce learning and facilitate practice change to enhance diagnostic accuracy\, care coordination\, and patient-centered outcomes in fibrosing ILDs. Register at https://medlearninggroup.zoom.us/webinar/register/WN_xlQkzfuTTIWslfO1Z0hKsQ#/registration
URL:https://www.pulmapp.com/event/optimizing-ild-management-with-dr-rohit-gupta/
LOCATION:Virtual
CATEGORIES:ILD
ATTACH;FMTTYPE=image/jpeg:https://www.pulmapp.com/wp-content/uploads/2026/09/1789745982424-76a0ff15-7277-4e58-a4ca-286aabde0307_1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260923T190000
DTEND;TZID=America/Los_Angeles:20260923T203000
DTSTAMP:20260922T124300
CREATED:20260917T203901Z
LAST-MODIFIED:20260917T222117Z
UID:19645-1790190000-1790195400@www.pulmapp.com
SUMMARY:The Evolving Landscape of Targeted Therapy in Asthma and COPD Care
DESCRIPTION:HRA® offers compensation of $800 to advanced practice providers for your consultative contributions during the event discussions\, responses to polling questions and completion of a post-event survey. \nPlease note: this is a non-CME\, independently produced program. All content is developed by the HCPLive® team. \nOVERVIEW \nHCPLive® Clinical Forum are regional roundtable discussions where an expert moderator has the opportunity to directly engage with health care professionals (HCPs) to present data\, medical advances\, and patient case scenarios. This leads to a moderated forum between attendees to gather insights on their community practice implementation of new science\, feedback on case scenarios\, as well as other information which impact the clinical decision making of local HCPs. \nThese forums serve as a platform for localized education and peer-to-peer collaborative discussions aiming to ultimately elevate and improve patient care. \nLEARNING OBJECTIVES \nAssess current drivers of treatment escalation in asthma and COPD\, including symptom burden\, exacerbation patterns\, biomarker thresholds\, and guideline recommendations.\nIdentify real-world barriers to timely use of biologic therapies in asthma and COPD and discuss strategies to create greater urgency in care.\nApply clinical trial data and emerging evidence to identify patient populations who might benefit from biologic therapies in asthma and COPD.
URL:https://www.pulmapp.com/event/the-evolving-landscape-of-targeted-therapy-in-asthma-and-copd-care-2/
LOCATION:Virtual
CATEGORIES:Asthma,COPD
ATTACH;FMTTYPE=image/jpeg:https://www.pulmapp.com/wp-content/uploads/2026/09/hcplive.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20260923T200000
DTEND;TZID=America/Denver:20260923T210000
DTSTAMP:20260922T124300
CREATED:20260909T183504Z
LAST-MODIFIED:20260909T183504Z
UID:19621-1790193600-1790197200@www.pulmapp.com
SUMMARY:APAPP: Sponsored Virtual Presentation
DESCRIPTION:PRESENTATION\nDate: Wednesday\, September 23rd\, 2026\nTime: 8:00 PM – 9:00 PM Eastern Time\nPresentation: Two Diseases\, One DUPIXENT: The Only Biologic Directly Inhibiting the Signaling of IL-4 & IL-13\, Two of the Key Drivers of Type 2 Inflammation\nPresented by: Kenny Larsen\, PA \nThis program is sponsored by our founding sponsors\, Sanofi and Regeneron and we thank them for their support.
URL:https://www.pulmapp.com/event/apapp-sponsored-virtual-presentation-2/
ATTACH;FMTTYPE=image/png:https://www.pulmapp.com/wp-content/uploads/2026/09/APAPP_Regeneron_Social-Post.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20260925T080000
DTEND;TZID=America/Denver:20260925T180000
DTSTAMP:20260922T124300
CREATED:20260831T185540Z
LAST-MODIFIED:20260831T185540Z
UID:19608-1790323200-1790359200@www.pulmapp.com
SUMMARY:2026 MSK Pulmo-Oncology Symposium
DESCRIPTION:Pulmo-oncology is an emerging discipline at the intersection of pulmonary medicine and oncology\, playing a critical role in the clinical care of patients with cancer. The respiratory system is often impacted by direct cancer involvement and toxicities stemming from the use of anti-neoplastic agents. Pre-existing pulmonary disorders affect patient outcomes and management decisions. Effective clinical management of pulmonary complications of cancer and its therapies requires an interdisciplinary approach. \nNow in its fourth year\, this symposium brings together globally recognized experts from multiple disciplines to present the latest advances in cancer therapies and best practices in the evaluation and management of lung disease. Through state-of-the-art presentations and interdisciplinary\, case-based discussions\, this symposium will explore key topics related to the care of cancer patients with pulmonary comorbidities and complications arising from cancer or its treatments. \nKey Topics Include  \n\nState-of-the-art updates in lung cancer treatment\nClinical strategies for management of drug toxicities\, symptoms\, and co-existing pulmonary conditions\nEmerging AI screening and continuous monitoring technologies as well as social media modalities into clinical management for cancer patients at risk of pulmonary complications\n\nComplex cases will be integrated throughout the program\, with dedicated time for interactive\, multidisciplinary panel discussions to foster meaningful engagement between participants and faculty. \nThis symposium is intended for healthcare professionals in pulmonology\, hematology/oncology\, and related disciplines involved in the care of patients with cancer or those with a special interest in this area.
URL:https://www.pulmapp.com/event/2026-msk-pulmo-oncology-symposium/
CATEGORIES:Cancer
ATTACH;FMTTYPE=image/png:https://www.pulmapp.com/wp-content/uploads/2026/08/msk-pulmo.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20261005T190000
DTEND;TZID=America/Chicago:20261005T203000
DTSTAMP:20260922T124300
CREATED:20260917T204118Z
LAST-MODIFIED:20260917T204156Z
UID:19648-1791226800-1791232200@www.pulmapp.com
SUMMARY:The Evolving Landscape of Targeted Therapy in Asthma and COPD Care
DESCRIPTION:HRA® offers compensation of $500 to advanced practice providers for your consultative contributions during the event discussions\, responses to polling questions and completion of a post-event survey. \nPlease note: this is a non-CME\, independently produced program. All content is developed by the HCPLive® team. \n\n\n\n\n\n\n\n\n\n\n\n\n\nOVERVIEW\n\n\n\n\nHCPLive® Clinical Forum are regional roundtable discussions where an expert moderator has the opportunity to directly engage with health care professionals (HCPs) to present data\, medical advances\, and patient case scenarios. This leads to a moderated forum between attendees to gather insights on their community practice implementation of new science\, feedback on case scenarios\, as well as other information which impact the clinical decision making of local HCPs. \nThese forums serve as a platform for localized education and peer-to-peer collaborative discussions aiming to ultimately elevate and improve patient care. \n\n\n\n\n\nLEARNING OBJECTIVES \n\nAssess current drivers of treatment escalation in asthma and COPD\, including symptom burden\, exacerbation patterns\, biomarker thresholds\, and guideline recommendations.\nIdentify real-world barriers to timely use of biologic therapies in asthma and COPD and discuss strategies to create greater urgency in care.\nApply clinical trial data and emerging evidence to identify patient populations who might benefit from biologic therapies in asthma and COPD.
URL:https://www.pulmapp.com/event/the-evolving-landscape-of-targeted-therapy-in-asthma-and-copd-care-3/
LOCATION:Virtual
CATEGORIES:Asthma,COPD
ATTACH;FMTTYPE=image/jpeg:https://www.pulmapp.com/wp-content/uploads/2026/09/hcplive.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20261006T190000
DTEND;TZID=America/Chicago:20261006T203000
DTSTAMP:20260922T124301
CREATED:20260917T204340Z
LAST-MODIFIED:20260917T204340Z
UID:19651-1791313200-1791318600@www.pulmapp.com
SUMMARY:The Evolving Landscape of Targeted Therapy in Asthma and COPD Care
DESCRIPTION:HRA® offers compensation of $350 to advanced practice providers for your consultative contributions during the event discussions\, responses to polling questions and completion of a post-event survey. \nPlease note: this is a non-CME\, independently produced program. All content is developed by the HCPLive® team. \n\n\n\n\n\n\n\n\n\n\n\n\n\nOVERVIEW\n\n\n\n\nHCPLive® Clinical Forum are regional roundtable discussions where an expert moderator has the opportunity to directly engage with health care professionals (HCPs) to present data\, medical advances\, and patient case scenarios. This leads to a moderated forum between attendees to gather insights on their community practice implementation of new science\, feedback on case scenarios\, as well as other information which impact the clinical decision making of local HCPs. \nThese forums serve as a platform for localized education and peer-to-peer collaborative discussions aiming to ultimately elevate and improve patient care. \n\n\n\n\n\nLEARNING OBJECTIVES \n\nAssess current drivers of treatment escalation in asthma and COPD\, including symptom burden\, exacerbation patterns\, biomarker thresholds\, and guideline recommendations.\nIdentify real-world barriers to timely use of biologic therapies in asthma and COPD and discuss strategies to create greater urgency in care.\nApply clinical trial data and emerging evidence to identify patient populations who might benefit from biologic therapies in asthma and COPD.
URL:https://www.pulmapp.com/event/the-evolving-landscape-of-targeted-therapy-in-asthma-and-copd-care-4/
LOCATION:Virtual
CATEGORIES:Asthma,COPD
ATTACH;FMTTYPE=image/jpeg:https://www.pulmapp.com/wp-content/uploads/2026/09/hcplive.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20261013T190000
DTEND;TZID=America/Denver:20261013T200000
DTSTAMP:20260922T124301
CREATED:20260918T161102Z
LAST-MODIFIED:20260918T161102Z
UID:19666-1791918000-1791921600@www.pulmapp.com
SUMMARY:APAPP Asthma Committee Journal Club
DESCRIPTION:Topic: APAPP Asthma Committee Journal Club\nArticle: Jayasooriya\, S. M.\, Devereux\, G.\, Soriano\, J. B.\, Singh\, N.\, Masekela\, R.\, Mortimer\, K.\, & Burney\, P. (2025). Asthma: epidemiology\, risk factors\, and opportunities for prevention and treatment. The lancet Respiratory medicine\, 13(8)\, 725-738. \nGlobal Epidemiology of Chronic Respiratory Disease 2 \nTime: Oct 13\, 2026 07:00 PM Eastern Time (US and Canada)\nJoin Zoom Meeting\nhttps://us02web.zoom.us/j/85224369575?pwd=AP3TvHk44YZtWgGQJ5rETngPgabIBC.1 \nMeeting ID: 852 2436 9575\nPasscode: 1qXH8Tr2 \nRSVP/Questions? Contact: borks@vcu.edu
URL:https://www.pulmapp.com/event/apapp-asthma-committee-journal-club/
LOCATION:Virtual
CATEGORIES:Asthma
ATTACH;FMTTYPE=image/png:https://www.pulmapp.com/wp-content/uploads/2026/09/Social-SeptemberOctober-2026-4.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261106
DTEND;VALUE=DATE:20261108
DTSTAMP:20260922T124301
CREATED:20260821T160611Z
LAST-MODIFIED:20260821T160611Z
UID:19588-1793923200-1794095999@www.pulmapp.com
SUMMARY:Florida Thoracic Society - Third Annual Conference
DESCRIPTION:We are excited to host our annual gathering of Pulmonary\, Critical Care and Sleep Medicine Professionals in Orlando\, FL November 6-7. This year’s event promises a dynamic lineup of educational sessions\, research presentations\, networking opportunities and industry engagement. \nAnticipated sessions include: \n\nThe Journey from screening to cure in Lung Cancer\nTwo is worse than one: ILD-PH\nECMO: not everybody agrees on the same things – A Pro-Con Debate\nAlpha-1 Antitrypsin Deficiency: The most common genetic disease we still miss\nBridging pediatric and adult pulmonary care: the transition to adulthood\nPediatric Programming: Tuberculosis in Florida – Complex Case with Interventional Pulmonology\nPediatric Programming: CF updates in newborn screening\nPediatric Programming: Pediatric Sleep\nExhibit Hall\n\nOnce registered\, you will receive a link to access our discounted room block at The Rosen Centre.
URL:https://www.pulmapp.com/event/florida-thoracic-society-third-annual-conference/
ATTACH;FMTTYPE=image/jpeg:https://www.pulmapp.com/wp-content/uploads/2026/08/fts_conference_flyer_2026.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
DTSTAMP:20260922T124301
CREATED:20260831T191436Z
LAST-MODIFIED:20260831T191436Z
UID:19611-1794528000-1794614399@www.pulmapp.com
SUMMARY:2026 USAsthma Summit
DESCRIPTION:Hosted by Allergy & Asthma Network in partnership with the American College of Allergy\, Asthma & Immunology (ACAAI)\, the Summit brings together patients\, caregivers\, clinicians\, public health leaders\, and community partners for a day full of learning\, conversation\, and inspiration. \nWhat’s on the Agenda for 2026?\nWe’re still finalizing speakers\, but here’s a sneak peek at some of the topics we’ll be exploring: \n\nThe State of Asthma in the United States\nPatients at the Center of Care & Policy\nEnvironmental Health Literacy\nHow Social Media & AI Are Reshaping Asthma Care\nIntegrating Mental Health Screening\nNew Federal Reforms and What They Mean for Asthma Care\n\n 
URL:https://www.pulmapp.com/event/2026-usasthma-summit/
CATEGORIES:Asthma
ATTACH;FMTTYPE=image/webp:https://www.pulmapp.com/wp-content/uploads/2026/08/USAsthmaSummitLogo.webp
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20261202T120000
DTEND;TZID=America/Denver:20261202T170000
DTSTAMP:20260922T124301
CREATED:20260811T160038Z
LAST-MODIFIED:20260811T160038Z
UID:19571-1796212800-1796230800@www.pulmapp.com
SUMMARY:2026 ILD Symposium
DESCRIPTION:An advanced CE-accredited afternoon symposium exploring the evolving treatment paradigm in interstitial lung disease\, including clinical development\, imaging\, CTD-ILD\, sarcoidosis\, and challenging ILD cases. \n\nEducational Outcome\nThis CE activity provides healthcare professionals with expert-led education on the evolving diagnosis and management of interstitial lung disease (ILD)\, including advances in screening\, treatment algorithms\, imaging\, and emerging therapies. Participants will gain practical insights into IPF\, PPF\, CTD-ILD\, sarcoidosis\, and complex ILD management strategies to support earlier recognition\, evidence-based treatment decisions\, and improved patient outcomes. \n\n\nCourse Objectives\nAfter completing this activity\, the participant should be better able to:\n\n\nDescribe the pathophysiology of interstitial lung disease and apply current screening protocols and treatment algorithms to optimize diagnosis and patient management\nEvaluate current and emerging approaches to ILD screening\, imaging\, and treatment algorithms\, as well as novel diagnostic technologies\nApply advances in ILD imaging to improve early detection\, disease monitoring\, and risk stratification across ILD subtypes\nRecognize the distinguishing clinical features and management considerations for special populations\, such as CTD-ILD and sarcoidosis\n\n\n\n\nTarget Audience\nThis activity is designed for pulmonologists\, rheumatologists\, radiologists\, cardiologists\, internists\, fellows\, advanced practice providers\, nurses\, pharmacists\, and other healthcare professionals engaged in the multidisciplinary care of patients with interstitial lung disease. \n\nFor more information and to register\, please visit https://www.ildsymposium.com/#home \n 
URL:https://www.pulmapp.com/event/2026-ild-symposium/
CATEGORIES:ILD
ATTACH;FMTTYPE=image/png:https://www.pulmapp.com/wp-content/uploads/2026/08/idl-conference-logo.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20261203T080000
DTEND;TZID=America/Denver:20261203T173000
DTSTAMP:20260922T124301
CREATED:20260811T163100Z
LAST-MODIFIED:20260811T163100Z
UID:19575-1796284800-1796319000@www.pulmapp.com
SUMMARY:23rd Annual Update in Pulmonary Hypertension
DESCRIPTION:This live CE-accredited activity is the only New England symposium that illustrates novel pathways implicated in the pathogenesis of pulmonary vascular disorders and provides state-of-the-art therapeutic approaches to the management of pulmonary hypertension. This education is accomplished via a combination of didactic lectures\, case-based plenary and breakout discussions that feature leading experts as presenters and panelists. All presentations will be based on current evidence-based guidelines\, research\, and patient-centered outcomes. \nEducational Outcome\nThis CE activity offers new and experienced healthcare providers state-of-the-art education\, recent data\, case discussions\, and practical guidance on the optimal screening and management of patients who have or are suspected of having pulmonary hypertension. It is expected that learners will utilize this education to make more informed treatment decisions that will measurably improve patient outcomes. \nObjectives\nAfter completing this activity\, the participant should be better able to: \n\nReview clinical trial evidence on the safety and efficacy of emerging drug treatment options for PH\, as well as novel pathways under development\nEvaluate new and existing therapeutic options for ILD-PH\, as well as strategies for earlier recognition and interventions for this patient population\nUtilize an interactive\, case-based learning approach in the discussion of managing PH patients with challenging comorbidities\, such as renal disease\, cancer\, non-methamphetamine drug-induced PH\, and others\nDevelop an evidence-based management plan for pulmonary hypertension that incorporates use of imaging modalities\, risk assessment tools\, pharmacologic strategies\, and routine follow-up to optimize outcomes\nDiscuss the use of combination therapies\, transition treatment strategies\, and add-on treatments in the management of PAH\nAssess Guideline-Directed Medical Therapy for HFpEF and HFrEF and novel pathways in development\nRecognize the complexities or treatment decisions in patients with CTD-associated PAH and differences from CTD-associated ILD-PH\nExplore how to incorporate a collaborative model between patients\, families\, and healthcare providers to optimize shared decision-making and improve outcomes
URL:https://www.pulmapp.com/event/23rd-annual-update-in-pulmonary-hypertension/
CATEGORIES:Pulmonary Hypertension
ATTACH;FMTTYPE=image/png:https://www.pulmapp.com/wp-content/uploads/2026/08/hypertension.png
END:VEVENT
END:VCALENDAR